Agathobacter

Agathobacter includes bacteria that turn undigested carbohydrates into butyrate. Researchers have found differences in its stool abundance in bowel disease and several other conditions. Those findings help explain why it appears on microbiome reports, but they don't establish what a particular result means for your health.

This is a research-stage marker. Its abundance has no validated diagnostic or treatment target, and changing the number has not been shown to improve health. A stool result describes part of your bacterial community at the time you collected the sample.

A Fiber Fermenter in the Lachnospiraceae Family

Agathobacter is a genus. A genus groups closely related bacterial species. It belongs to the Lachnospiraceae family within the phylum Bacillota, formerly called Firmicutes. Its best-studied human gut species is Agathobacter rectalis, which older papers and some reports call Eubacterium rectale.

These bacteria grow without oxygen and ferment carbohydrates. Cultured members of the genus produce butyrate and other fermentation products. Butyrate is a fatty acid that cells lining the colon use as fuel. Experiments in cells and mice also show effects on the intestinal barrier and immune cells that restrain inflammation. Those experiments establish biological mechanisms; they don't show that a higher Agathobacter stool result gives you those benefits.

What the Stool Number Represents

The test analyzes bacterial DNA in stool and reports the proportion assigned to Agathobacter. This is called relative abundance. It describes the sampled stool community, without directly measuring living bacterial activity, the bacteria attached to your intestinal lining, or butyrate production.

Because the result is a proportion, it depends on the other bacteria in the sample. Agathobacter's share can rise when another group shrinks even if its own amount stays unchanged. Species-level findings about A. rectalis also don't automatically apply to the combined genus-level result.

Inflammatory Bowel Disease

Stool studies have linked Agathobacter to inflammatory bowel disease, although the findings vary with the population and disease state. In one study of ulcerative colitis, it was more abundant during remission than during an exacerbation. This supports investigating the genus as a marker of disease activity, but it doesn't establish that a low result identifies a flare.

In a study of 131 people with inflammatory bowel disease, particular bacterial DNA sequences assigned to Agathobacter were less abundant in those with a history of manifestations outside the bowel, such as joint, skin, or eye problems. The association remained after adjustments that included disease severity, previous surgery, and disease type. The study did not show that stool testing could predict who would develop those complications.

An earlier pediatric study linked a broader Eubacterium rectale-related bacterial group to response to anti-TNF treatment. That study used a different bacterial grouping and measurement approach, so it is related evidence rather than validation of this genus-level result. Agathobacter has not been established as a way to choose an IBD drug or confirm that treatment is working.

Colon Cancer and Precancerous Changes

Some studies have found less Agathobacter in people who already have colorectal cancer. A small Indonesian study reported depletion compared with healthy controls. In a separate surveillance study, people with ulcerative colitis and precancerous or cancerous tissue changes had less Agathobacter and more Escherichia-Shigella than those without those changes. These comparisons cannot establish whether bacterial depletion preceded the lesions.

Researchers are also studying combinations of bacteria as possible screening tools. A study of people whose fecal immunochemical test was already positive found that the amount of blood detected by that test performed better than microbiome models for identifying cancer. Adding microbiome information offered some improvement in identifying precancerous lesions, but the findings came from this selected screening population. They do not validate Agathobacter alone as a cancer marker.

Kidney Health

IgA nephropathy involves deposits containing an immune protein in the kidney's filters. A small study of people with this disease found changes in stool bacteria involved in butyrate production. A. rectalis was the most abundant species in the subgroup whose kidney function remained more stable. That is a finding about one species within Agathobacter, and its prominence in that subgroup does not establish that the genus predicts kidney decline. The study provides no validated way to use this stool result for kidney monitoring.

Heart and Artery Findings

Some cardiovascular studies have associated higher Agathobacter abundance with less favorable outcomes. In 211 adults under cardiology care, followed for several years, researchers compared two whole-community profiles. The profile enriched in Agathobacter, Blautia, and another bacterial group had more major cardiovascular events than the other profile after adjustment. That comparison concerns the combined microbial profiles, so it cannot be assigned to Agathobacter alone.

In a study using baseline stool samples from adults with treated HIV, higher Agathobacter abundance was associated with progression of carotid artery thickening or plaque during follow-up, after adjustment for cardiovascular risk factors. A small study of older adults with high cholesterol also found that Agathobacter shares correlated with triglycerides and LDL cholesterol. A study of atrial fibrillation found lower abundance in people with the condition than in controls.

These results do not establish a direction to aim for. They also do not show that measuring this genus improves cardiovascular risk assessment beyond established blood tests and clinical risk factors.

Allergies in Children

Among 1,440 school-age children, a bacterial DNA sequence assigned to Agathobacter was associated with doctor-diagnosed inhalant allergy. This was a finding about a particular sequence within the genus, not a validated relationship between your total Agathobacter percentage and allergy risk. The study assessed an association with existing allergy and did not show that the bacterium caused it.

Other Reported Associations

Most of these studies compared people with and without a condition at one point in time. Disease, diet, medication, and changes in bowel habits can all contribute to the differences. The findings have not established a clinical use for measuring Agathobacter in these conditions.

• Lupus: one study found a lower Agathobacter share than in healthy controls. Disease activity and treatment were also associated with changes in the gut community.
• Celiac disease: people without symptoms had more Agathobacter than those with classic symptoms in one study. This does not establish that the bacteria protected against symptoms.
• Primary sclerosing cholangitis: a stool study found lower Agathobacter abundance in this disease, which affects the bile ducts.
• Mental health and eating disorders: separate studies reported lower stool Agathobacter or sequences assigned to it in obsessive-compulsive disorder, subthreshold depression, and severe anorexia nervosa.
• Migraine and stroke: higher abundance correlated with less severe headache pain in one migraine study. Another study found lower abundance after lacunar stroke, which affects small blood vessels deep in the brain.

Interpreting the Evidence

The evidence supports studying Agathobacter as part of a larger microbial community. It does not support classifying an individual result as healthy or unhealthy. Lower abundance in a disease group can reflect the disease or its treatment, and associations in the opposite direction make a universal higher-is-better interpretation especially unreliable.

Research panels combining several bacterial markers have shown promising diagnostic performance. One IBD study reported numerically better discrimination between IBD and irritable bowel syndrome than fecal calprotectin in a pilot comparison. That result applies to the particular multi-bacteria panel and study population. It does not establish diagnostic accuracy for Agathobacter alone.

When Results Can Be Misleading

• Laboratory methods: DNA extraction, sequencing, analysis software, and reference databases can change the reported proportion and the bacteria assigned to the genus.
• Relative abundance: changes elsewhere in the community can raise or lower the percentage without a matching change in the amount of Agathobacter.
• Recent antibiotics or bowel preparation: these can alter the stool community. The direction and duration of the change are not predictable from this genus alone.
• Illness and bowel habits: a sample collected during an illness or a change in bowel habits may differ from your usual stool profile.
• Collection and storage: contamination, delays, and storage conditions can affect the sample. The collection kit's preservation and shipping instructions matter.

Tracking Your Trend

Repeated measurements can describe changes in your stool community, but there is no validated amount of change that establishes better health or treatment success. Using the same laboratory and collection approach reduces some sources of variation. It does not make a rising or falling Agathobacter result a validated measure of recovery.